Deutsche Bank AG acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 126,286 shares of the biotechnology company's stock, valued at approximately $7,226,000. Deutsche Bank AG owned approximately 0.07% of BioMarin Pharmaceutical as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in BMRN. Rice Hall James & Associates LLC bought a new stake in shares of BioMarin Pharmaceutical in the second quarter worth about $14,203,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $39,000. Monaco Asset Management SAM bought a new stake in BioMarin Pharmaceutical during the 2nd quarter worth approximately $10,582,000. Persistent Asset Partners Ltd acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter worth approximately $4,574,000. Finally, Plato Investment Management Ltd bought a new position in BioMarin Pharmaceutical in the second quarter valued at approximately $115,000. Institutional investors and hedge funds own 98.71% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on BMRN shares. Wall Street Zen raised shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. UBS Group reaffirmed a "neutral" rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Citigroup increased their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Morgan Stanley boosted their price target on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Bank of America reduced their price objective on BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating for the company in a research report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $88.83.
Get Our Latest Analysis on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
Shares of BMRN opened at $65.07 on Tuesday. The stock has a market capitalization of $12.60 billion, a price-to-earnings ratio of 175.86, a PEG ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a 12 month low of $49.26 and a 12 month high of $70.98. The firm has a fifty day simple moving average of $60.85 and a 200 day simple moving average of $57.93. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same period in the previous year, the business earned $1.44 EPS. The company's revenue was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts forecast that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.
About BioMarin Pharmaceutical
(
Free Report)
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company's commercial portfolio includes several approved therapies targeting inherited disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
